|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||







* Department of Medical Chemistry, University of Szeged;
Department of Comparative Physiology, University of Szeged;
Department of Analytical and Inorganic Chemistry, University of Szeged;
Institute of Biophysics, Biological Research Centre, Hungarian Academy of Sciences;
|| Department of Biology, Juhász Gyula College, University of Szeged; and
¶ Institute of Biochemistry, Biological Research Center of the Hungarian Academy of Sciences, Szeged, Hungary
1Correspondence: Department of Medical Chemistry, University of Szeged, Dóm Square 8, Szeged 6720, Hungary. E-mail: szegv{at}mdche.szote.u-szeged.hu
ABSTRACT
The underlying cause of Alzheimers disease (AD) is thought to be the ß-amyloid aggregates formed mainly by Aß142 peptide. Protective pentapeptides [e.g., Leu-Pro-Phe-Phe-Asp (LPFFD)] have been shown to prevent neuronal toxicity of Aß142 by arresting and reversing fibril formation. Here we report that an endogenous tetrapeptide, endomorphin-2 (End-2, amino acid sequence: YPFF), defends against Aß142 induced neuromodulatory effects at the cellular level. Although End-2 does not interfere with the kinetics of Aß fibrillogenesis according to transmission electron microscopic studies and quasielastic light scattering measurements, it binds to Aß142 during aggregation, as revealed by tritium-labeled End-2 binding assay and circular dichroism measurements. The tetrapeptide attenuates the inhibitory effect on cellular redox activity of Aß142 in a dose-dependent manner, as measured by 3-(4,5-dimethylthiazolyl-2)-2,-5-diphenyltetrazolium bromide (MTT) assay. In vitro and in vivo electrophysiological experiments show that End-2 also protects against the field excitatory postsynaptic potential attenuating and the NMDA-evoked response-enhancing effect of Aß142. Studies using [D-Ala (2) , N-Me-Phe (4) , Gly (5) -ol]-enkephalin (DAMGO), a µ-opioid receptor agonist, show that the protective effects of the tetrapeptide are not µ-receptor modulated. The endogenous tetrapeptide End-2 may serve as a lead compound for the drug development in the treatment of AD.Szegedi, V., Juhász, G., Rózsa, E., Juhász-Vedres, G., Datki, Z., Fülöp, L., Bozsó, Z., Lakatos, A., Laczkó, I., Farkas, T., Kis, Z., Tóth, G., Soós, K., Zarándi, M., Budai, D., Toldi, J., Penke, B. Endomorphin-2, an endogenous tetrapeptide, protects against Aß142 in vitro and in vivo.
This article has been cited by other articles:
![]() |
R. Minkeviciene, S. Rheims, M. B. Dobszay, M. Zilberter, J. Hartikainen, L. Fulop, B. Penke, Y. Zilberter, T. Harkany, A. Pitkanen, et al. Amyloid {beta}-Induced Neuronal Hyperexcitability Triggers Progressive Epilepsy J. Neurosci., March 18, 2009; 29(11): 3453 - 3462. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |